التفاصيل البيبلوغرافية
| العنوان: |
Anaplastic mixed gliomas and anaplastic oligodendroglioma in children: results from the CCGÂ 945 experience. |
| المؤلفون: |
Douglas Hyder, Lillian Sung, Ian Pollack, Floyd Gilles, Allen Yates, Richard Davis, James Boyett, Jonathan Finlay |
| المصدر: |
Journal of Neuro-Oncology; May2007, Vol. 83 Issue 1, p1-8, 8p |
| مستخلص: |
Abstract Purpose  To review interpathologist diagnosis variability and survival of children treated for either anaplastic mixed glioma (AMG) or anaplastic oligodendroglioma (AO) with surgery, irradiation and chemotherapy. Patients and methods  Two hundred and fifty patients with an institutional diagnosis of malignant glioma were enrolled on Childrenâs Cancer Group CCG-945 between 1985 and 1991, and administered vincristine during involved field radiotherapy, then six cycles of prednisone, lomustine and, vincristine; or two cycles of âeight-drugs-in-one-dayâ (8-in-1) chemotherapy then involved-field radiotherapy followed by six cycles of 8-in-1 chemotherapy. Central review of institutional pathology was post hoc by five experienced neuropathologists. Results  Twenty-six children had institutional diagnoses of AMG and four had AO. Complete resection and cerebral tumor location was associated with better overall survival (OS) in patients with institutional diagnoses of AMG. However, central review established that only nine of 26 children had AMG: either mixed oligoastrocytoma (MOA) or anaplastic mixed oligoastrocytoma (AOA) and only one had AO. Central review revealed five more patients with AMG, but none with AO. Institutional and CCG central review diagnoses of AMG or AO had poor Jaccard reliabilities of 0.29 and 0.25 respectively. Five-year EFS and OS for five children with centrally confirmed MOA was 50  20%, with four centrally confirmed AOA was 37.5  17%. After central review, small samples made tests for differences in survival between regimes impossible. Conclusion  Diagnosis of these tumors is challenging, with only 35% of institutional diagnoses confirmed for AMG and 25% for AO, and survival among children with these tumors is poor, despite intensive therapy. This suggests reliable diagnostic markers and new therapeutic approaches are needed. [ABSTRACT FROM AUTHOR] |
|
Copyright of Journal of Neuro-Oncology is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Find this article in full text from Springer Verlag. 
Full Text Finder